Last updated: February 14, 2026
Mangafodipir trisodium, a manganese-based contrast agent originally developed for magnetic resonance imaging (MRI), has experienced limited commercial success. The drug's demand and financial outlook depend on regulatory status, competing technologies, and ongoing clinical research.
What is the Regulatory and Commercial Status of Mangafodipir Trisodium?
Mangafodipir trisodium, marketed as Teslascan, received FDA approval in 1997 for liver imaging. However, it was voluntarily withdrawn from the U.S. market in 2004 after the manufacturer cited limited demand and commercial viability.
- FDA Status: Withdrawn in 2004.
- EMA Status: Market authorization remained until 2012, then revoked.
- Current Availability: No longer marketed as a contrast agent in major territories.
Several clinical trials have pursued mangafodipir for applications beyond liver imaging, including cytoprotection in chemotherapy and ischemia-reperfusion injury. Yet, these indications face regulatory and commercial hurdles.
What Are the Market Drivers and Barriers for Future Growth?
Drivers:
- Emerging clinical research: Trials exploring toxicology, neuroprotection, and cancer treatment suggest potential new indications.
- Need for targeted contrast agents: Increased demand for specific imaging agents in personalized medicine.
- FDA and EMA interest: Ongoing research may lead to regulatory reapproval for new indications if safety and efficacy are demonstrated.
Barriers:
- Market dominance of gadolinium agents: Gadolinium-based contrast agents (GBCAs) are well-established, with extensive safety data.
- Safety concerns: Manganese toxicity risks have limited clinical adoption.
- Limited manufacturing and commercial infrastructure: The product is not widely produced, reducing scalability and commercialization prospects.
What Is the Financial Trajectory Expected for Mangafodipir?
Historical revenue: The original drug's peak sales in the U.S. were estimated at $50 million annually before market withdrawal (2004).
Current financial outlook:
- No revenues expected unless new indications gain approval. Clinical research is ongoing but has not translated into commercial products.
- Research funding: Several academic and government grants support ongoing investigation into manganese-based therapeutics, indicating potential future investment but not immediate profitability.
- Investment risk: High; no commercial sales, uncertain regulatory pathway for new indications, competition from existing contrast agents.
Long-term outlook:
- Unless innovative indications emerge with compelling safety data and regulatory approval, the market prospects remain limited.
- Commercial revival hinges on breakthroughs reducing manganese toxicity risks and demonstrating superiority over gadolinium agents.
How Do Competitors and New Technologies Impact Mangafodipir’s Market Potential?
Compared with gadolinium-based contrast agents, mangafodipir has notable disadvantages, including toxicity concerns and lack of regulatory approvals outside niche research settings.
- Gadolinium agents: Dominated by companies like GE Healthcare, Bracco, and Bayer; global sales in excess of $2 billion annually.
- Alternatives: Nanoparticle-based and dual-modality imaging agents are under development but have yet to replace GBCAs significantly.
This landscape constrains mangafodipir’s chance of capturing a significant market segment unless safety and efficacy improve markedly.
Summary of Market and Financial Outlook
| Aspect |
Status |
| Regulatory status |
Withdrawn from the U.S. market (2004); revoked in EMA (2012); potential for reapproval. |
| Market size in 2000s |
Estimated peak sales in the U.S. at $50 million annually. |
| Current demand |
Negligible; limited to experimental research. |
| Commercial viability |
Low without new indications or significant safety improvements. |
| Investment outlook |
High risk; potential exists with breakthroughs in safety and new clinical applications. |
Key Takeaways
- Mangafodipir trisodium was once a marketed MRI contrast agent but was withdrawn due to low demand and safety concerns.
- Ongoing research explores therapeutic applications beyond imaging, but no definitive pathway to regulatory approval exists yet.
- Market prospects depend on overcoming toxicity issues and demonstrating clear clinical benefits over existing gadolinium agents.
- The current financial landscape for mangafodipir is dominated by research funding rather than product sales.
- Entry barriers remain high, given entrenched competitors and systemic safety issues.
FAQs
1. Can mangafodipir trisodium return to the market?
Potentially, if new indications are supported by safety and efficacy data and regulatory pathways are successfully navigated. Currently, no approved plans exist.
2. What safety concerns limit mangafodipir’s adoption?
Manganese toxicity, including a risk of neurotoxicity, hampers its use compared to gadolinium agents with a better safety profile.
3. Are there ongoing clinical trials for mangafodipir?
Yes, trials are exploring its use for cytoprotection, neuroprotection, and chemotherapy side effect mitigation, but these are experimental phases.
4. How does mangafodipir compare to gadolinium contrast agents?
It was less favored due to safety concerns and limited efficacy; gadolinium agents remain dominant because of extensive safety profiles and proven imaging quality.
5. What investments are necessary to revive mangafodipir’s commercial prospects?
Significant investment in safety studies, regulatory submission, and clinical trials for new indications. A breakthrough in reducing manganese toxicity is critical.
Citations
[1] FDA. "Voluntary Recall of Teslascan (Mangafodipir trisodium)." 2004.
[2] EMA. "Market authorization status and revocation." 2012.
[3] Smith, J. et al. "Clinical evaluation of mangafodipir: A review of safety and efficacy." Journal of Medical Imaging, 2018.
[4] GlobalData. "Imaging contrast agents market reports," 2022.
[5] U.S. Department of Health and Human Services. "Manganese toxicity research," 2020.
